{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T03:45:21Z","timestamp":1775706321415,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T00:00:00Z","timestamp":1645056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1007\/s40121-022-00599-8","type":"journal-article","created":{"date-parts":[[2022,2,17]],"date-time":"2022-02-17T03:02:33Z","timestamp":1645066953000},"page":"913-924","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety of 8- or 12 Weeks of Glecaprevir\/Pibrentasvir in Patients with Evidence of Portal Hypertension"],"prefix":"10.1007","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8220-065X","authenticated-orcid":false,"suffix":"Jr.","given":"Robert S.","family":"Brown","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simone I.","family":"Strasser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Emmett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew S.","family":"Topp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Burroughs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordan J.","family":"Feld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,2,17]]},"reference":[{"key":"599_CR1","volume-title":"Global progress report on hiv, viral hepatitis and sexually transmitted infections","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Global progress report on hiv, viral hepatitis and sexually transmitted infections. Geneva: WHO; 2021."},{"issue":"12","key":"599_CR2","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1001\/jamaoncol.2017.3055","volume":"3","author":"T Akinyemiju","year":"2017","unstructured":"Akinyemiju T, Abera S, Ahmed M, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683\u201391.","journal-title":"JAMA Oncol"},{"issue":"4","key":"599_CR3","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1016\/j.jhep.2018.12.001","volume":"70","author":"Z Liu","year":"2019","unstructured":"Liu Z, Jiang Y, Yuan H, et al. The trends in incidence of primary liver cancer caused by specific etiologies: results from the global burden of disease study 2016 and implications for liver cancer prevention. J Hepatol. 2019;70(4):674\u201383.","journal-title":"J Hepatol"},{"issue":"3","key":"599_CR4","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.jhep.2015.05.022","volume":"63","author":"R de Franchis","year":"2015","unstructured":"de Franchis R. Expanding consensus in portal hypertension: report of the baveno vi consensus workshop: stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015;63(3):743\u201352.","journal-title":"J Hepatol"},{"issue":"5","key":"599_CR5","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.jhep.2020.08.018","volume":"73","author":"European Association for the Study of the Liver","year":"2020","unstructured":"European Association for the Study of the Liver. Easl recommendations on treatment of hepatitis c: final update of the series. J Hepatol. 2020;73(5):1170\u2013218.","journal-title":"J Hepatol"},{"issue":"3","key":"599_CR6","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.jhep.2019.10.020","volume":"72","author":"RS Brown Jr","year":"2020","unstructured":"Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir\/pibrentasvir for 8 weeks in treatment-naive patients with chronic hcv genotypes 1\u20136 and compensated cirrhosis: the expedition-8 trial. J Hepatol. 2020;72(3):441\u20139.","journal-title":"J Hepatol"},{"issue":"11","key":"599_CR7","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1016\/j.cgh.2020.06.044","volume":"18","author":"E Zuckerman","year":"2020","unstructured":"Zuckerman E, Gutierrez JA, Dylla DE, et al. Eight weeks of treatment with glecaprevir\/pibrentasvir is safe and efficacious in an integrated analysis of treatment-na\u00efve patients with hepatitis c virus infection. Clin Gastroenterol Hepatol. 2020;18(11):2544-53.e6.","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"599_CR8","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/S2468-1253(18)30341-8","volume":"4","author":"T Asselah","year":"2019","unstructured":"Asselah T, Lee SS, Yao BB, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients with chronic hepatitis c virus genotype 5 or 6 infection (endurance-5,6): an open-label, multicentre, phase 3b trial. Lancet Gastroenterol Hepatol. 2019;4(1):45\u201351.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"599_CR9","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1093\/cid\/ciy220","volume":"67","author":"JK Rockstroh","year":"2018","unstructured":"Rockstroh JK, Lacombe K, Viani RM, et al. Efficacy and safety of glecaprevir\/pibrentasvir in patients coinfected with hepatitis c virus and human immunodeficiency virus type 1: the expedition-2 study. Clin Infect Dis. 2018;67(7):1010\u20137.","journal-title":"Clin Infect Dis"},{"issue":"9","key":"599_CR10","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S2468-1253(20)30086-8","volume":"5","author":"L Wei","year":"2020","unstructured":"Wei L, Wang G, Alami NN, et al. Glecaprevir-pibrentasvir to treat chronic hepatitis c virus infection in asia: Two multicentre, phase 3 studies\u2014a randomised, double-blind study (voyage-1) and an open-label, single-arm study (voyage-2). Lancet Gastroenterol Hepatol. 2020;5(9):839\u201349.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9","key":"599_CR11","doi-asserted-by":"publisher","first-page":"4033","DOI":"10.1007\/s12325-020-01449-0","volume":"37","author":"P Lampertico","year":"2020","unstructured":"Lampertico P, Mauss S, Persico M, et al. Real-world clinical practice use of 8-week glecaprevir\/pibrentasvir in treatment-na\u00efve patients with compensated cirrhosis. Adv Ther. 2020;37(9):4033\u201342.","journal-title":"Adv Ther"},{"key":"599_CR12","unstructured":"Abbvie. Maviret [Summary of Product Characteristics]. 2021 [cited 2021 September 10]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/maviret-epar-product-information_en.pdf."},{"key":"599_CR13","unstructured":"AbbVie. Mavyret. North Chicago, IL; 2021."},{"issue":"10","key":"599_CR14","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X Forns","year":"2017","unstructured":"Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis c virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (expedition-1): A single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17(10):1062\u20138.","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"599_CR15","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1002\/hep.29541","volume":"67","author":"D Wyles","year":"2018","unstructured":"Wyles D, Poordad F, Wang S, et al. Glecaprevir\/pibrentasvir for hepatitis c virus genotype 3 patients with cirrhosis and\/or prior treatment experience: a partially randomized phase 3 clinical trial. Hepatology. 2018;67(2):514\u201323.","journal-title":"Hepatology"},{"issue":"15","key":"599_CR16","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1056\/NEJMoa1704053","volume":"377","author":"E Gane","year":"2017","unstructured":"Gane E, Lawitz E, Pugatch D, et al. Glecaprevir and pibrentasvir in patients with hcv and severe renal impairment. N Engl J Med. 2017;377(15):1448\u201355.","journal-title":"N Engl J Med"},{"issue":"2","key":"599_CR17","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1002\/hep.29510","volume":"67","author":"H Toyoda","year":"2018","unstructured":"Toyoda H, Chayama K, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in japanese patients with chronic genotype 2 hepatitis c virus infection. Hepatology. 2018;67(2):505\u201313.","journal-title":"Hepatology"},{"issue":"5","key":"599_CR18","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1111\/liv.14320","volume":"40","author":"E Lawitz","year":"2020","unstructured":"Lawitz E, Flisiak R, Abunimeh M, et al. Efficacy and safety of glecaprevir\/pibrentasvir in renally impaired patients with chronic hcv infection. Liver Int. 2020;40(5):1032\u201341.","journal-title":"Liver Int"},{"key":"599_CR19","doi-asserted-by":"publisher","first-page":"100257","DOI":"10.1016\/j.aohep.2020.09.002","volume":"20","author":"M Peribanez-Gonzalez","year":"2021","unstructured":"Peribanez-Gonzalez M, Cheinquer H, Rodrigues L, et al. Efficacy and safety of glecaprevir\/pibrentasvir in treatment-naive adults with chronic hepatitis c virus genotypes 1\u20136 in brazil. Ann Hepatol. 2021;20:100257.","journal-title":"Ann Hepatol"},{"issue":"6","key":"599_CR20","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1007\/s12325-021-01753-3","volume":"38","author":"X Forns","year":"2021","unstructured":"Forns X, Feld JJ, Dylla DE, et al. Safety of patients with hepatitis c virus treated with glecaprevir\/pibrentasvir from clinical trials and real-world cohorts. Adv Ther. 2021;38(6):3409\u201326.","journal-title":"Adv Ther"},{"issue":"1","key":"599_CR21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/hep.31841","volume":"74","author":"MM Jonas","year":"2021","unstructured":"Jonas MM, Rhee S, Kelly DA, et al. Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in children with chronic hcv: Part 2 of the dora study. Hepatology. 2021;74(1):19\u201327.","journal-title":"Hepatology"},{"issue":"7","key":"599_CR22","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1111\/liv.14937","volume":"41","author":"H Klinker","year":"2021","unstructured":"Klinker H, Naumann U, Rossle M, et al. Glecaprevir\/pibrentasvir for 8 weeks in patients with compensated cirrhosis: safety and effectiveness data from the german hepatitis c-registry. Liver Int. 2021;41(7):1518\u201322.","journal-title":"Liver Int"},{"issue":"22","key":"599_CR23","doi-asserted-by":"publisher","first-page":"5236","DOI":"10.3390\/jcm10225236","volume":"10","author":"PY Su","year":"2021","unstructured":"Su PY, Chen YY, Lai JH, et al. Real-world experience of chronic hepatitis c-related compensated liver cirrhosis treated with glecaprevir\/pibrentasvir: a multicenter retrospective study. J Clin Med. 2021;10(22):5236.","journal-title":"J Clin Med"},{"issue":"5","key":"599_CR24","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/liv.14829","volume":"41","author":"H Wedemeyer","year":"2021","unstructured":"Wedemeyer H, Erren P, Naumann U, et al. Glecaprevir\/pibrentasvir is safe and effective in hepatitis c patients with cirrhosis: real-world data from the german hepatitis c-registry. Liver Int. 2021;41(5):949\u201355.","journal-title":"Liver Int"},{"issue":"15","key":"599_CR25","doi-asserted-by":"publisher","first-page":"3280","DOI":"10.3390\/jcm10153280","volume":"10","author":"D Zarebska-Michaluk","year":"2021","unstructured":"Zarebska-Michaluk D, Jaroszewicz J, Parfieniuk-Kowerda A, et al. Effectiveness and safety of pangenotypic regimens in the most difficult to treat population of genotype 3 hcv infected cirrhotics. J Clin Med. 2021;10(15):3280.","journal-title":"J Clin Med"},{"issue":"3","key":"599_CR26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.jhep.2019.10.022","volume":"72","author":"P Ferenci","year":"2020","unstructured":"Ferenci P. Are all cirrhotic patients equal? J Hepatol. 2020;72(3):389\u201390.","journal-title":"J Hepatol"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00599-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-022-00599-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-022-00599-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T08:11:50Z","timestamp":1649923910000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-022-00599-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,17]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["599"],"URL":"https:\/\/doi.org\/10.1007\/s40121-022-00599-8","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,17]]},"assertion":[{"value":"1 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}